Experts propose selecting radiotherapy–drug regimens using efficacy, scheduling, late toxicity, biomarkers, and patient-reported outcomes rather than maximum tolerated dose alone.
USP15 stabilized FIS1, suppressed oxidative phosphorylation, and increased radiosensitivity; metformin restored radiation response in USP15-low bladder cancer models.
Gold nanoparticles increased proton-induced clonogenic killing from 4 Gy onward, with similar sensitization using 20- and 50-nm particles.
Triple oHSV, radiotherapy and IGF1R blockade suppressed YAP1, produced tumour regressions and prolonged survival in glioblastoma and breast cancer models.